Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2a multicenter randomized, double-blind, placebo-controlled study assessing the efficacy and safety of VENT-03 in adults with active Cutaneous Lupus Ery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• VENT-03

Snippet

Sponsor: Ventus Therapeutics U.S., Inc. | Conditions: Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus | Phase 2 | Status: RECRUITING